Alnylam Pharmaceuticals Inc. (ALNY)
Alnylam Stock Is a Blockbuster Biopharma In the Making
Biopharmaceutical stock Alnylam Pharmaceuticals (NASDAQ: ALNY ) is riding a tsunami of hope that a treatment for a rare heart condition receives Food & Drug Administration approval. Although it has several drugs already on the market, the biopharma is not yet profitable.
35% Surge Just the Beginning? Alnylam's Stock Poised for Massive Gains on Heart Drug Success.
Could Alnylam Pharmaceuticals (NASDAQ: ALNY ) become a household name in 2024? At the very least, the company should be well known in the medical community.
7 Cheap Biotech Stocks With Major Upside Potential
Intuitively, the case for biotechnology-related investments comes across rather obviously: the concept of healthcare should be a permanent one. And because of this permanence, the expected market value of the ecosystem should be massive.
What's Next For Alnylam Stock After A 60% Rise In A Week?
Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 60% in a week. This can be attributed to positive data from a late-stage clinical trial for its cardiovascular drug, Amvuttra.
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
HELIOS-B Shines Bright And Gives Alnylam Pharmaceuticals Another Blockbuster
HELIOS-B Phase III study of Amvuttra in patients with ATTR-CM succeeded across all metrics, showing significant benefits in both the combined study population and monotherapy groups. Amvuttra showed strong efficacy in reducing all-cause mortality and cardiovascular events, with positive results in secondary endpoints and a good safety profile. Results support the use of Amvuttra as monotherapy or in combination with stabilizers in people with ATTR-CM, potentially generating billions in incremental revenue for Alnylam.
Alnylam Stock Soars on Strong Results in Heart Drug Study
Shares of Alnylam Pharmaceuticals (ALNY) skyrocketed over 31% in early trading Monday after the biopharma firm announced strong results from a late-stage study of its RNA interference drug for a rare heart condition.
Alnylam Pharmaceuticals reports promising heart disease trial results
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Shares of the biopharmaceutical company are now trading at a year-to-date high of $220.
Alnylam Pharma Shares Surge 30% After Rare Heart Disease Drug Succeeds
Shares of Alnylam Pharmaceuticals rose by over 32%, the company's largest single-day gain in nearly two years, after announcing its drug vutrisiran helped reduce the number of deaths and cardiovascular events in a study of patients with a rare heart disease.
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
Heart disease drugmaker Alnylam (NASDAQ: ALNY ) stock rose sharply on the success of a Phase 3 study of its heart drug, vutrisiran. The drug is also sold as Amvuttra.
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Monday, Alnylam Pharmaceuticals Inc ALNY revealed topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Alnylam Stock Soars After Positive Results From Heart Disease Study
The drugmaker says the study met the primary endpoint and demonstrated significant improvements across all secondary endpoints.
